查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2086110

腫瘤生物相似藥市場：依產品類型、治療適應症、給藥途徑、病患年齡層及通路分類－2026-2032年全球市場預測

Oncology Biosimilars Market by Product Type, Therapeutic Indication, Route Of Administration, Patient Age Group, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，腫瘤領域的生物相似藥市場將成長至 183.8 億美元，複合年成長率為 13.04%。

主要市場統計數據
基準年 2025 77.9億美元
預計年份：2026年 86.6億美元
預測年份 2032 183.8億美元
複合年成長率 (%) 13.04%

腫瘤生物相似藥市場概覽

腫瘤生物相似藥正在改變癌症治療格局，它們為固體癌、骨髓惡性腫瘤和支持治療中使用的參考生物製藥提供高度相似且臨床等效的替代方案。美國食品藥物管理局(FDA)、歐洲藥品管理局 (EMA)、世界衛生組織 (WHO) 和各國監管機構呼籲採用「全面證據」方法，在批准前全面評估分析相似性、藥物動力學、免疫抗原性和臨床療效。

腫瘤生物相似藥市場的變革性變化

該領域的格局正在從最初的生物相似藥上市浪潮轉向基於生命週期的競爭、產品組合合約和循證應用。醫院和癌症治療網路在評估生物相似藥時，不僅關注採購價格，還擴大採用替代療法方案、處方藥清單管理、真實世界臨床結果和總治療成本等指標。

人工智慧（AI）的累積影響

人工智慧 (AI) 在癌症生物相似藥的研發、生產和商業化的各個階段都發揮著累積價值。 AI 驅動的分析有助於最佳化細胞株、監控流程、檢測偏差、收集監管資訊、監測文獻以及檢測藥物監測訊號，從而使團隊能夠更快、更有效地管理複雜生物製藥的變異性。

主要腫瘤生物相似藥市場的關鍵區域洞察

北美仍然是腫瘤生物相似藥的高價值市場，其中美國處於主導地位。在美國，聯邦醫療保險B部分（Medicare Part B）的報銷趨勢、整合醫療網路、腫瘤治療路徑以及保險公司協議都在影響著生物相似藥的使用。在加拿大，生物相似藥的推廣應用正透過省級和全國性的政策機制逐步推進，這些機制日益重視具有成本效益的生物製藥，同時也維持著加拿大衛生署嚴格的生物相似藥審查標準。

關於引入生物相似藥治療癌症的關鍵群體特定見解

歐盟透過統一的科學評估、藥物安全監測、互通性指導以及基於競標的廣泛採購，鞏固了全球對生物相似藥的信心。七國集團（G7）在產生臨床證據、創新健保報銷體系、提供先進的癌症治療以及滿足對高品質生物製藥的需求方面繼續發揮核心作用。同時，北約成員國中有許多高所得國家，它們的醫療衛生體系注重供應穩定、採購韌性以及不間斷地提供必要的癌症治療。

來自影響競爭地位的關鍵國家的洞見

美國仍然是最大的商業性機會市場，這主要得益於其在參考生技藥品的支出、癌症治療網路的整合、聯邦醫療保險（Medicare）的報銷規則以及臨床醫生在使用FDA批准的生物類似藥方面的經驗積累。加拿大正透過省級報銷政策和全國性審查機制擴大生物相似藥的可及性，而墨西哥則透過公共採購和墨西哥聯邦衛生產品監管局（COFEPRIS）的監管來加強生物相似藥的使用。巴西擁有大規模的癌症治療需求，並已製定了完善的巴西國家衛生監督局（ANVISA）法規和公共醫療保健系統採購制度，是拉丁美洲重要的可近性市場。

為行業領導者提供的實用建議

產業領導者應根據​​癌症適應症的複雜性、原廠藥專利到期、監管可行性以及支付方處方劑量調整意願等因素，優先發展其腫瘤生物相似藥產品組合。商業性成功不僅取決於價格降低。企業還需要穩定的供應、腫瘤專科醫學教育、病患支持、透明的轉換數據以及符合醫療服務提供者經濟狀況的合約模式。

調查方法

本分析以檢驗，結合了第一手資料和第二手資料。二級資訊來源包括監管資料庫、產品附加檔、同行評審的癌症文獻、衛生技術評估 (HTA) 出版物、報銷政策、臨床指南、藥物警戒文件以及來自 FDA、EMA、WHO 和國家主管機關的指導意見。

結論

用於癌症治療的生物相似藥已從概念驗證階段發展成為減輕癌症治療經濟負擔的重要支柱。監管機構的信心、臨床實踐中日益成長的認知、支付方的壓力、公共採購以及在不降低治療標準的前提下繼續控制癌症生技藥品支出的必要性，都推動了生物類似藥的持續應用。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 腫瘤生物相似藥市場：依產品類型分類

  • 單株抗體
    • Rituximab
    • 曲妥珠單抗
    • Bevacizumab
  • 荷爾蒙療法
  • 成長要素
    • Filgrastim
    • Pegfilgrastim

第8章：腫瘤生物相似藥市場：依治療適應症分類

  • 乳癌
  • 結腸癌
  • 胃癌
  • 肺癌
  • 非何傑金氏淋巴瘤

第9章：腫瘤生物相似藥市場：依給藥途徑分類

  • 靜脈輸液
  • 皮下注射

第10章：腫瘤生物相似藥市場：依患者年齡層別分類

  • 兒童患者
  • 成年患者
  • 老年患者

第11章：腫瘤生物相似藥市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房
  • 專科藥房

第12章 腫瘤生物相似藥市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章：腫瘤生物相似藥市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 腫瘤生物相似藥市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Accord Healthcare Ltd.
  • Alkem Laboratories Ltd.
  • Amgen Inc.
  • Apotex Inc.
  • BIOCAD
  • Biocon Biologics Limited
  • Celltrion Inc.
  • Coherus BioSciences, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Henlius Biopharmaceuticals Co., Ltd.
  • Hospira Inc.
  • Intas Pharmaceuticals Ltd.
  • Novartis International AG
  • Organon & Co.
  • Pfizer Inc.
  • Sandoz Group AG
  • STADA Arzneimittel AG
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Zydus Lifesciences Ltd.
Product Code: MRR-036C5CF3A8CC

The Oncology Biosimilars Market is projected to grow by USD 18.38 billion at a CAGR of 13.04% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.79 billion
Estimated Year [2026] USD 8.66 billion
Forecast Year [2032] USD 18.38 billion
CAGR (%) 13.04%

Oncology Biosimilars Market Introduction

Oncology biosimilars are reshaping cancer care by providing highly similar, clinically comparable alternatives to reference biologics used in solid tumors, hematologic malignancies, and supportive care. Regulators, including the U.S. FDA, European Medicines Agency, World Health Organization, and national agencies, require a totality-of-evidence approach covering analytical similarity, pharmacokinetics, immunogenicity, and clinical performance before approval.

Demand is supported by patent expirations for major monoclonal antibodies, pressure on oncology drug budgets, and payer interest in sustainable access. Biosimilars for trastuzumab, bevacizumab, rituximab, and pegfilgrastim have demonstrated that competition can expand treatment affordability while preserving the standards clinicians expect for biologic cancer therapies.

Transformative Shifts in the Oncology Biosimilars Landscape

The landscape is shifting from first-wave biosimilar launches toward lifecycle-based competition, portfolio contracting, and evidence-driven adoption. Hospitals and oncology networks are increasingly evaluating biosimilars through therapeutic interchange protocols, formulary governance, real-world outcomes, and total cost-of-care measures rather than acquisition price alone.

Regulatory maturity is also transforming the market. Europe's long-standing biosimilar framework, the FDA's expanding oncology biosimilar approvals, and growing reliance pathways in emerging markets are reducing uncertainty. At the same time, manufacturing scale, supply assurance, physician education, and patient confidence remain decisive differentiators for organizations competing in oncology biologics.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is adding cumulative value across oncology biosimilar development, manufacturing, and commercialization. AI-enabled analytics support cell-line optimization, process monitoring, deviation detection, regulatory intelligence, literature surveillance, and pharmacovigilance signal detection, helping teams manage complex biologic variability with greater speed and consistency.

The impact is strongest when AI complements validated scientific methods rather than replacing them. Regulators continue to rely on robust comparability evidence, quality-by-design controls, and post-market safety monitoring. As FDA and EMA policy discussions on AI in drug development evolve, organizations that pair advanced analytics with transparent governance are better positioned to improve timelines, compliance, and launch execution.

Key Regional Insights Across Major Oncology Biosimilar Markets

North America remains a high-value oncology biosimilars region, led by the United States, where Medicare Part B reimbursement dynamics, integrated delivery networks, oncology practice pathways, and payer contracting influence utilization. Canada is advancing through provincial and pan-Canadian policy mechanisms that increasingly favor cost-effective biologic options while maintaining Health Canada's rigorous biosimilar review standards.

Europe is the most mature adoption environment, supported by EMA experience dating back to the first EU biosimilar approval in 2006, national tendering, physician familiarity, and established pharmacovigilance systems. Asia-Pacific is expanding as China, India, Japan, South Korea, and Australia combine regulatory modernization with local biologics manufacturing capacity, oncology infrastructure investment, and increasing acceptance of biosimilar monoclonal antibodies. Latin America is growing through ANVISA, COFEPRIS, and regional access initiatives that prioritize affordability and public-sector procurement. The Middle East is advancing through national cancer strategies, hospital modernization, and centralized purchasing, while Africa shows rising demand through oncology capacity building, donor-supported access programs, public procurement, and growing recognition of biosimilars as tools for improving biologic cancer therapy availability.

Key Group Insights for Oncology Biosimilar Adoption

The European Union anchors global biosimilar confidence through harmonized scientific assessment, pharmacovigilance, interchangeability guidance, and widespread tender-based purchasing. G7 countries remain central to clinical evidence generation, reimbursement innovation, advanced oncology care delivery, and premium biologic demand, while NATO members overlap with many high-income health systems focused on supply security, procurement resilience, and uninterrupted access to essential oncology medicines.

BRICS markets are increasingly important because China, India, Brazil, Russia, and South Africa combine large oncology populations with industrial policy supporting biologics manufacturing, technology transfer, and domestic medicine security. ASEAN countries are improving regulatory convergence, reliance pathways, and hospital access to cost-efficient biologics, while the GCC is using centralized procurement, specialist cancer centers, and national oncology strategies to accelerate availability of oncology biosimilars across public and private health systems.

Key Country Insights Shaping Competitive Positioning

The United States remains the largest commercial opportunity, driven by reference biologic spending, oncology network consolidation, Medicare reimbursement rules, and growing clinician experience with FDA-approved biosimilars. Canada is expanding access through provincial reimbursement policies and pan-Canadian review mechanisms, while Mexico is strengthening biosimilar use through public procurement and COFEPRIS oversight. Brazil combines large oncology demand with established ANVISA regulation and public health system purchasing, making it a key Latin American access market.

The United Kingdom, Germany, France, Italy, and Spain benefit from mature oncology infrastructure, specialist prescribing capacity, and national health technology assessment, although adoption varies by tendering, gainsharing, hospital formularies, and prescribing autonomy. Russia emphasizes localized supply and medicine security. China and India are pivotal manufacturing and demand centers, supported by large patient populations, domestic biologics capabilities, and evolving regulatory pathways. Japan, South Korea, and Australia maintain rigorous regulatory standards and strong oncology systems, making them influential reference markets for quality expectations, switching practices, real-world evidence, and physician acceptance.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize oncology biosimilar portfolios around high-burden cancer indications, reference-product loss of exclusivity, regulatory feasibility, and payer willingness to shift volume. Commercial success requires more than price reduction; organizations need reliable supply, oncology-specific medical education, patient support, transparent switching data, and contracting models aligned with provider economics.

Manufacturers should invest in advanced characterization, scalable biologics manufacturing, quality systems, pharmacovigilance readiness, and real-world evidence generation. Partnerships with hospitals, group purchasing organizations, cancer networks, and national health systems can accelerate uptake. In emerging markets, local regulatory expertise, cold-chain reliability, stakeholder education, and affordability programs are essential for sustainable oncology biosimilar adoption.

Research Methodology

The analysis is built on triangulated secondary and primary research. Secondary sources include regulatory databases, product labels, peer-reviewed oncology literature, health technology assessment publications, reimbursement policies, clinical guidelines, pharmacovigilance documents, and guidance from FDA, EMA, WHO, and national authorities.

Market interpretation is validated through expert review of competitive launches, approval pathways, manufacturing capacity, pricing behavior, procurement practices, reimbursement frameworks, and adoption trends. The research applies structured data normalization, cross-source verification, evidence weighting, and quality checks to ensure insights reflect verified, data-backed market behavior rather than unverified assumptions, without relying on market sizing, market share, or forecasting.

Conclusion

Oncology biosimilars have moved from proof-of-concept to an established pillar of cancer-care affordability. Their continued adoption is supported by regulatory confidence, expanding clinical familiarity, payer pressure, public procurement, and the ongoing need to manage biologic oncology spending without compromising treatment standards.

The next phase will reward organizations that combine scientific rigor, manufacturing reliability, AI-enabled operational efficiency, strong pharmacovigilance, and region-specific market access strategies. Stakeholders that build trust with oncologists, payers, regulators, pharmacists, and patients will be best positioned to capture long-term value in the global oncology biosimilars market.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Oncology Biosimilars Market, by Product Type

  • 7.1. Monoclonal Antibodies
    • 7.1.1. Rituximab
    • 7.1.2. Trastuzumab
    • 7.1.3. Bevacizumab
  • 7.2. Hormonal Therapies
  • 7.3. Growth Factors
    • 7.3.1. Filgrastim
    • 7.3.2. Pegfilgrastim

8. Oncology Biosimilars Market, by Therapeutic Indication

  • 8.1. Breast Cancer
  • 8.2. Colorectal Cancer
  • 8.3. Gastric Cancer
  • 8.4. Lung Cancer
  • 8.5. Non-Hodgkin's Lymphoma

9. Oncology Biosimilars Market, by Route Of Administration

  • 9.1. Intravenous Infusion
  • 9.2. Subcutaneous Injection

10. Oncology Biosimilars Market, by Patient Age Group

  • 10.1. Pediatric Patients
  • 10.2. Adult Patients
  • 10.3. Geriatric Patients

11. Oncology Biosimilars Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies
  • 11.4. Specialty Pharmacies

12. Oncology Biosimilars Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Oncology Biosimilars Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Oncology Biosimilars Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Accord Healthcare Ltd.
  • 16.2. Alkem Laboratories Ltd.
  • 16.3. Amgen Inc.
  • 16.4. Apotex Inc.
  • 16.5. BIOCAD
  • 16.6. Biocon Biologics Limited
  • 16.7. Celltrion Inc.
  • 16.8. Coherus BioSciences, Inc.
  • 16.9. Dr. Reddy's Laboratories Ltd.
  • 16.10. Henlius Biopharmaceuticals Co., Ltd.
  • 16.11. Hospira Inc.
  • 16.12. Intas Pharmaceuticals Ltd.
  • 16.13. Novartis International AG
  • 16.14. Organon & Co.
  • 16.15. Pfizer Inc.
  • 16.16. Sandoz Group AG
  • 16.17. STADA Arzneimittel AG
  • 16.18. Teva Pharmaceutical Industries Ltd.
  • 16.19. Viatris Inc.
  • 16.20. Zydus Lifesciences Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ONCOLOGY BIOSIMILARS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL ONCOLOGY BIOSIMILARS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL ONCOLOGY BIOSIMILARS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL ONCOLOGY BIOSIMILARS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL ONCOLOGY BIOSIMILARS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL ONCOLOGY BIOSIMILARS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL RITUXIMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL RITUXIMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL RITUXIMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TRASTUZUMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TRASTUZUMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TRASTUZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BEVACIZUMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BEVACIZUMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BEVACIZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HORMONAL THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HORMONAL THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HORMONAL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GROWTH FACTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GROWTH FACTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GROWTH FACTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL FILGRASTIM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL FILGRASTIM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL FILGRASTIM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PEGFILGRASTIM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PEGFILGRASTIM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PEGFILGRASTIM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BREAST CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BREAST CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BREAST CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL COLORECTAL CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL COLORECTAL CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL COLORECTAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GASTRIC CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GASTRIC CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GASTRIC CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL LUNG CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL LUNG CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NON-HODGKIN'S LYMPHOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NON-HODGKIN'S LYMPHOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NON-HODGKIN'S LYMPHOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL INTRAVENOUS INFUSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL INTRAVENOUS INFUSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL INTRAVENOUS INFUSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SUBCUTANEOUS INJECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SUBCUTANEOUS INJECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SUBCUTANEOUS INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PEDIATRIC PATIENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PEDIATRIC PATIENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PEDIATRIC PATIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ADULT PATIENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ADULT PATIENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ADULT PATIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GERIATRIC PATIENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GERIATRIC PATIENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GERIATRIC PATIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL SPECIALTY PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL SPECIALTY PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL SPECIALTY PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA ONCOLOGY BIOSIMILARS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA ONCOLOGY BIOSIMILARS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE ONCOLOGY BIOSIMILARS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE ONCOLOGY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST ONCOLOGY BIOSIMILARS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST ONCOLOGY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN ONCOLOGY BIOSIMILARS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. GCC ONCOLOGY BIOSIMILARS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 132. GCC ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. GCC ONCOLOGY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 134. GCC ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 135. GCC ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 136. GCC ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 137. GCC ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GCC ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION ONCOLOGY BIOSIMILARS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION ONCOLOGY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS ONCOLOGY BIOSIMILARS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 148. BRICS ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. BRICS ONCOLOGY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. G7 ONCOLOGY BIOSIMILARS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 156. G7 ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. G7 ONCOLOGY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 158. G7 ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 159. G7 ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 160. G7 ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 161. G7 ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. G7 ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. NATO ONCOLOGY BIOSIMILARS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 164. NATO ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. NATO ONCOLOGY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 166. NATO ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 167. NATO ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 168. NATO ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. NATO ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. NATO ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 173. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. CANADA ONCOLOGY BIOSIMILARS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 181. CANADA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. CANADA ONCOLOGY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 183. CANADA ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 184. CANADA ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 185. CANADA ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 186. CANADA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 187. CANADA ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. MEXICO ONCOLOGY BIOSIMILARS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 189. MEXICO ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. MEXICO ONCOLOGY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 191. MEXICO ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 192. MEXICO ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 193. MEXICO ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 194. MEXICO ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. MEXICO ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 196. BRAZIL ONCOLOGY BIOSIMILARS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 197. BRAZIL ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. BRAZIL ONCOLOGY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 199. BRAZIL ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 200. BRAZIL ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 201. BRAZIL ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 202. BRAZIL ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 203. BRAZIL ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED KINGDOM ONCOLOGY BIOSIMILARS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED KINGDOM ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED KINGDOM ONCOLOGY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED KINGDOM ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED KINGDOM ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED KINGDOM ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED KINGDOM ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED KINGDOM ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 212. GERMANY ONCOLOGY BIOSIMILARS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 213. GERMANY ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. GERMANY ONCOLOGY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 215. GERMANY ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 216. GERMANY ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 217. GERMANY ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 218. GERMANY ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 219. GERMANY ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 220. FRANCE ONCOLOGY BIOSIMILARS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. FRANCE ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. FRANCE ONCOLOGY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 223. FRANCE ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 224. FRANCE ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 225. FRANCE ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 226. FRANCE ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 227. FRANCE ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 228. RUSSIA ONCOLOGY BIOSIMILARS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 229. RUSSIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. RUSSIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 231. RUSSIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 232. RUSSIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 233. RUSSIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 234. RUSSIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 235. RUSSIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 236. ITALY ONCOLOGY BIOSIMILARS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 237. ITALY ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. ITALY ONCOLOGY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 239. ITALY ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 240. ITALY ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 241. ITALY ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 242. ITALY ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 243. ITALY ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 244. SPAIN ONCOLOGY BIOSIMILARS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 245. SPAIN ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. SPAIN ONCOLOGY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 247. SPAIN ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 248. SPAIN ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 249. SPAIN ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 250. SPAIN ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 251. SPAIN ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA ONCOLOGY BIOSIMILARS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 260. INDIA ONCOLOGY BIOSIMILARS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 261. INDIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. INDIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 263. INDIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 264. INDIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 265. INDIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 266. INDIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 267. INDIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 268. JAPAN ONCOLOGY BIOSIMILARS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 269. JAPAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. JAPAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 271. JAPAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 272. JAPAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 273. JAPAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 274. JAPAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 275. JAPAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 276. AUSTRALIA ONCOLOGY BIOSIMILARS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 277. AUSTRALIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. AUSTRALIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 279. AUSTRALIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 280. AUSTRALIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 281. AUSTRALIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 282. AUSTRALIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 283. AUSTRALIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 284. SOUTH KOREA ONCOLOGY BIOSIMILARS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 285. SOUTH KOREA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. SOUTH KOREA ONCOLOGY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 287. SOUTH KOREA ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROWTH FACTORS, 2018-2032 (USD MILLION)
  • TABLE 288. SOUTH KOREA ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2018-2032 (USD MILLION)
  • TABLE 289. SOUTH KOREA ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 290. SOUTH KOREA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 291. SOUTH KOREA ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)